Iconovo AB (publ) announced that the company strengthens its customer offering in the Novel Pharmaceuticals business segment by the launch of Iconovo Accelerator Program - a structured approach for pharmaceutical companies to obtain non-dilutive funding of commercially attractive projects. This is made possible through a newly established collaboration with the consulting firm Argentum, which specializes in structuring and managing application processes for EU funding and has so far helped secure over SEK 20 billion in research and development funding for its clients. The purpose of Iconovo Accelerator Program is to finance projects that are to a significant extent performed by Iconovo, which in turn can contribute to an increased earnings capacity for the company.

Sales of medicines and vaccines for diseases where inhalers can provide significant benefits amount to almost USD 100 billion. Asthma, COPD, pulmonary hypertension and several types of vaccinations are some examples. Iconovo has already established four collaboration agreements in the Novel Pharmaceutical business segment, where it assists R&D-driven pharmaceutical companies in the development of completely new treatments based on the company's unique proprietary inhalers.

There are however challenges in financing new innovative pharmaceutical projects, and many smaller companies lack access to expertise that can optimize opportunities to benefit from the substantial research grants awarded each year by the EU. is launched to offer customers strategic and Iconovo Accelerator Program operational support in connection with application processes for public funding of projects that are based on the company's inhaler platforms.